Back to Journals » Therapeutics and Clinical Risk Management » Circulating Biomarkers and AI in Therapeutics and Clinical Risk Management: From Molecular Signals to Precision Medicine
Therapeutics and Clinical Risk Management
- View all (2615)
- Volume 22, 2026 (59)
- Volume 21, 2025 (162)
- Volume 20, 2024 (86)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Journal Articles:
- Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome (1)
- Machine Learning in the Realm of Therapeutics and Clinical Risk Management (1)
- Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications (1)
- Anticholinergic Therapies for the Treatment of Asthma (7)
Circulating Biomarkers and AI in Therapeutics and Clinical Risk Management: From Molecular Signals to Precision Medicine
Circulating biomarkers are increasingly reshaping the landscape of modern medicine by enabling minimally invasive, dynamic assessment of disease processes across diverse clinical settings. Among these, cell-free DNA (cfDNA) has emerged as a particularly versatile analyte, offering insights into tissue damage, clonal evolution, and therapeutic response in real time. Beyond its established role in oncology, cfDNA and related circulating markers are gaining traction in cardiovascular disease, transplantation monitoring, infectious diseases, and chronic inflammatory conditions, where early detection and longitudinal surveillance remain critical challenges.